NAVLE Cardiovascular

Feline Congestive Heart Failure Study Guide

📅 March 28, 2026 ⏱ 25 min read

Overview and Clinical Importance

Congestive heart failure (CHF) is a clinical syndrome in which the heart fails to maintain adequate cardiac output to meet the body's metabolic demands, resulting in fluid accumulation in the lungs (pulmonary edema) or thoracic/abdominal cavities (pleural effusion, ascites). In cats, CHF is most commonly caused by hypertrophic cardiomyopathy (HCM), which affects up to 15% of the domestic cat population. Unlike dogs, cats with CHF more frequently present with pleural effusion rather than pulmonary edema alone.

CHF represents a significant category on the NAVLE, requiring understanding of pathophysiology, clinical recognition, diagnostic approach, and emergency stabilization. Early recognition and appropriate management can significantly improve survival and quality of life.

Left-Sided CHF (L-CHF)	Right-Sided CHF (R-CHF)
Mechanism: Elevated left atrial pressure causes blood to back up into pulmonary veins	Mechanism: Elevated right atrial pressure causes systemic venous congestion
Manifestations: Pulmonary edema, Pleural effusion (common in cats), Respiratory distress, Tachypnea	Manifestations: Ascites, Hepatomegaly, Jugular venous distension, Peripheral edema (rare in cats)
Most Common Cause: HCM, RCM, DCM	Most Common Cause: Pulmonary hypertension, Tricuspid dysplasia, ARVC

Pathophysiology of Feline CHF

Understanding Cardiac Function

The heart functions as a pump with four chambers. The left side receives oxygenated blood from the lungs and pumps it systemically, while the right side receives deoxygenated blood and pumps it to the lungs. Heart failure develops when either side cannot effectively pump blood forward.

Left-Sided vs Right-Sided Heart Failure

High-YieldIn cats, left-sided CHF commonly presents with BOTH pulmonary edema AND pleural effusion (approximately 60-65% of cases). This is different from dogs where pleural effusion more typically indicates right-sided failure. Always perform thoracentesis before radiographs in severely dyspneic cats.

Type	Prevalence	Pathology	Key Features
Hypertrophic (HCM)	Most common (58-68%)	LV wall thickening greater than 6mm, Diastolic dysfunction	SAM, LVOTO possible. Breeds: Maine Coon, Ragdoll, Sphynx
Restrictive (RCM)	Second most common (15-20%)	Normal LV walls, Impaired diastolic filling due to fibrosis	Severe LA enlargement, High ATE risk, Poor prognosis
Dilated (DCM)	Rare (less than 5%)	Thin LV walls, Chamber dilation, Systolic dysfunction	Taurine deficiency (historic). FS less than 25%
Unclassified/NCM	10-15%	Does not fit HCM, RCM, or DCM criteria	May show features of multiple types

Etiology: Feline Cardiomyopathies

The primary causes of CHF in cats are the cardiomyopathies. Understanding their classification is essential for the NAVLE.

Classification of Feline Cardiomyopathies

Board Tip - Memory Aid: "THICK, STIFF, WEAK" = HCM (thick walls), RCM (stiff walls), DCM (weak walls). Remember: HCM is the MOST COMMON cardiomyopathy in cats. DCM is RARE since taurine supplementation of commercial diets.

Finding	Description and Clinical Significance
Vertebral Heart Score (VHS)	Normal: 7.5 +/- 0.3 vertebrae. VHS greater than 8.0 suggests cardiomegaly; greater than 9.3 highly associated with heart disease
Valentine Heart Shape	Classic appearance on DV/VD view indicating left atrial enlargement (biatrial enlargement)
Left Atrial Enlargement	Dorsal deviation of trachea/carina on lateral view; bulge at 2-3 o'clock position on DV view
Pulmonary Venous Distension	Pulmonary veins larger than accompanying arteries; indicates elevated left atrial pressure
Pulmonary Edema Pattern	CATS: Patchy, diffuse, or ventral distribution (NOT perihilar like dogs). Interstitial to alveolar pattern
Pleural Effusion	Pleural fissure lines, retraction of lung lobes from chest wall, border effacement of cardiac silhouette

Clinical Presentation

Common Clinical Signs

Cats with CHF often present acutely with respiratory distress, though signs may have been present subclinically. Key presentation features include:

Tachypnea/Dyspnea: Resting respiratory rate greater than 40 breaths/min; open-mouth breathing indicates severe distress
Orthopnea: Sternal recumbency with elbows abducted, extended neck
Muffled heart/lung sounds: Indicates pleural effusion
Pulmonary crackles: Indicates pulmonary edema (less common finding in cats)
Heart murmur: Present in approximately 50% of cats with cardiomyopathy
Gallop rhythm (S3 or S4): Highly suggestive of cardiomyopathy
Hypothermia: Poor prognostic indicator; indicates cardiogenic shock
Lethargy, anorexia, weight loss: Chronic signs often missed by owners

High-YieldApproximately 50% of cats with heart disease do NOT have a detectable murmur! A gallop rhythm (extra heart sound) is more specific for feline cardiomyopathy than a murmur. Always consider cardiac disease in any cat with acute respiratory distress.

Parameter	Normal Value	Clinical Significance
LV Wall Thickness (diastole)	Less than 6 mm	Greater than 6 mm = HCM; Rule out hypertension, hyperthyroidism first
LA:Ao Ratio	Less than 1.5	Greater than 1.6 = LA enlargement; greater than 2.0 = high ATE risk
Fractional Shortening (FS)	35-65%	Less than 25-30% = systolic dysfunction (DCM); Often hyperdynamic in HCM
Spontaneous Echo Contrast (SEC)	Absent	"Smoke" in LA indicates blood stasis; HIGH RISK for ATE

Diagnostic Approach

Initial Stabilization First

CRITICAL: Cats in respiratory distress are extremely fragile. Minimize stress during initial evaluation. Provide oxygen supplementation and allow the cat to assume a comfortable position before extensive diagnostics.

Thoracic Radiography

Radiographs are essential for confirming CHF but should only be performed once the patient is stable enough to tolerate positioning.

Radiographic Findings in Feline CHF

NAVLE TipFeline pulmonary edema has a VARIABLE distribution (patchy, diffuse, ventral, or caudodorsal) - NOT the classic perihilar "butterfly" pattern seen in dogs. Don't rule out cardiogenic edema based on distribution alone!

Echocardiography

Echocardiography is the gold standard for diagnosing cardiomyopathy type and severity. Key parameters include:

Cardiac Biomarkers

NT-proBNP (N-terminal pro-B-type Natriuretic Peptide)

NT-proBNP is released by cardiac myocytes in response to wall stretch and volume overload. It is useful for:

Differentiating cardiac vs respiratory causes of dyspnea
Screening for occult cardiomyopathy
Monitoring disease progression

High-YieldNT-proBNP can also be measured in pleural fluid! This is useful when serum cannot be obtained safely. Pleural NT-proBNP greater than 260 pmol/L suggests cardiogenic effusion.

NT-proBNP Value	Interpretation
Less than 100 pmol/L	Normal - heart disease unlikely
100-270 pmol/L	Equivocal - echocardiography recommended
Greater than 270 pmol/L	Elevated - CHF likely in dyspneic cat (sensitivity 90%, specificity 88%)

Treatment of Feline CHF

Emergency Stabilization

MINIMIZE STRESS - Cats in CHF are extremely fragile. Handle minimally, provide oxygen, allow comfortable positioning.

Chronic Management

Once stabilized, transition to oral maintenance therapy. Drug selection depends on cardiomyopathy type and presence of LVOTO.

NAVLE TipPimobendan is CONTROVERSIAL in cats with obstructive HCM (LVOTO). While recent studies suggest it may be safe, traditional teaching advises AVOIDING positive inotropes in obstructive disease as they may worsen dynamic outflow obstruction. Know both perspectives for the NAVLE.

Intervention	Dose/Method	Notes
Oxygen Therapy	Flow-by, mask, or oxygen cage (40-60%)	First priority. Minimize handling.
Furosemide	1-2 mg/kg IV/IM q1-4h initially	Mainstay of CHF therapy. Can repeat q1-2h in severe cases. Monitor for azotemia.
Thoracentesis	Aseptic technique, 20-22G needle/butterfly	PERFORM BEFORE RADIOGRAPHS if significant pleural effusion suspected. Rapid relief.
Sedation (if needed)	Butorphanol 0.1-0.2 mg/kg IV/IM	Anxiolysis without significant respiratory depression. Avoid acepromazine (hypotension).

Arterial Thromboembolism (ATE)

Arterial thromboembolism, also known as "saddle thrombus" or FATE (Feline Aortic Thromboembolism), is a devastating complication of cardiomyopathy in cats. Thrombi form in the enlarged left atrium and embolize to peripheral arteries.

Clinical Presentation - The "5 Ps"

Pain: Severe, acute onset. Vocalization, distress
Paralysis/Paresis: Lower motor neuron signs in affected limb(s)
Pulselessness: Absent femoral pulses
Pallor/Purple: Cyanotic or pale nail beds and foot pads
Poikilothermia (Polar): Cold affected limbs compared to unaffected

Location of Thromboembolism

ATE Treatment and Prognosis

Treatment is supportive and aimed at preventing clot extension and managing pain:

Analgesia: ESSENTIAL. Opioids (methadone, buprenorphine, fentanyl CRI)
Antithrombotic therapy: Clopidogrel 18.75 mg PO q24h. May add LMWH (enoxaparin 0.75-1 mg/kg SC q6h)
CHF management: Furosemide if concurrent heart failure
Physical therapy: Gentle passive range of motion as recovery progresses

Memory Aid - 5 Ps of ATE: "PAINFUL, PARALYZED, PULSELESS, PALE/PURPLE, POLAR" - If you see a cat with acute onset hindlimb paralysis, severe pain, and absent femoral pulses, think ATE until proven otherwise!

Drug	Dose	Indication and Notes
Furosemide	1-2 mg/kg PO q12-24h	Essential for CHF. Titrate to lowest effective dose. Monitor renal values.
Clopidogrel	18.75 mg PO q24h	Antithrombotic for ATE prevention. Start in ALL cats with LA:Ao greater than 1.6. Superior to aspirin.
ACE Inhibitor (Enalapril/Benazepril)	0.25-0.5 mg/kg PO q12-24h	Neurohormonal modulation. Evidence of benefit limited in cats with HCM.
Pimobendan	0.25-0.3 mg/kg PO q12h	Inodilator. Use in DCM and non-obstructive HCM. AVOID in HCM with LVOTO (controversial).
Atenolol	6.25-12.5 mg/cat PO q12-24h	Beta-blocker. For tachyarrhythmias or LVOTO. AVOID in acute CHF (negative inotrope).
Taurine	250-500 mg/cat PO q12h	Supplement in DCM or suspected deficiency. Recovery can occur with supplementation.

Monitoring and Follow-up

Home Monitoring - Sleeping Respiratory Rate (SRR)

Owner monitoring of sleeping respiratory rate is the most valuable home monitoring tool for detecting early CHF recurrence:

Normal SRR: Less than 30 breaths/minute
Target for CHF cats: Less than 36 breaths/minute when sleeping
Warning sign: Persistent increase greater than 40 breaths/minute warrants reevaluation
Smartphone apps: Cardalis app available for tracking

Prognosis

Prognosis varies significantly based on underlying cardiomyopathy type and presence of complications:

HCM with CHF: Median survival 6-18 months with treatment
RCM: Generally poorer prognosis than HCM
DCM with taurine deficiency: Good prognosis with supplementation if diagnosed early
ATE complication: Guarded; 50-75% euthanized at presentation
Hyperthyroid cardiomyopathy: May be reversible with treatment of hyperthyroidism

Location	Frequency	Clinical Signs
Distal Aorta (Saddle)	~70-72%	Bilateral or unilateral hindlimb paralysis
Brachial Artery	~15-20%	Unilateral forelimb paralysis
Renal, Mesenteric, Cerebral	Less than 10%	Variable; often undetected or fatal

Prognostic Factor	Implication
One limb affected + motor function present	Better prognosis
Both hindlimbs affected, no motor function	Guarded to poor prognosis
Hypothermia (less than 37.2°C)	Poor prognosis
Concurrent CHF at presentation	Shorter survival (median 77 days vs 223 days)
Median survival with clopidogrel	443 days (vs 192 days with aspirin alone)

Practice NAVLE Questions

Test your knowledge with 10,000+ exam-style questions, detailed explanations, and timed exams.

Start Your Free Trial →